{"id":"rapamycin-calcitriol-combination","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Anemia"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The combination of rapamycin and calcitriol targets the mTOR pathway, which regulates cell growth and proliferation, and the VDR pathway, which is involved in calcium and phosphate homeostasis. This dual targeting may enhance the therapeutic efficacy of the combination in certain diseases.","oneSentence":"Rapamycin-calcitriol combination inhibits the mammalian target of rapamycin (mTOR) and vitamin D receptor (VDR) pathways.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:16.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT03140449","phase":"PHASE3","title":"Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2013-09-05","conditions":"Facial Angiofibroma","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sirolimus-Rocaltrol combination"],"phase":"phase_3","status":"active","brandName":"Rapamycin-calcitriol combination","genericName":"Rapamycin-calcitriol combination","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rapamycin-calcitriol combination inhibits the mammalian target of rapamycin (mTOR) and vitamin D receptor (VDR) pathways. Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}